Compositions for Treatment of Attention Deficit Hyperactivity Disorder

• US 20140212483A1
• Filed: 03/31/2014
• Published: 07/31/2014
• Est. Priority Date: 03/23/2011
• Status: Active Grant

• Current Assignee: Ironshore Pharmaceuticals & Development, Inc.
• Original Assignee: Ironshore Pharmaceuticals & Development, Inc.
• Inventors: Lickrish, David, Zhang, Feng
• Granted Patent: US 8,927,010 B2
• Time in Patent Office: Days
• US Class Current: 424/451
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/4458 only substituted in position 2, e.g. methylphenidate
• CPC Class Codes: A61K 9/1676 having a drug-free core with discrete complete coating layer containing drug adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921
• CPC Class Codes: A61K 9/4808 characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084
• CPC Class Codes: A61K 9/5026 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/5047 Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/5073 having two or more different coatings optionally including drug-containing subcoatings
• CPC Class Codes: A61K 9/5084 Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs tablets containing such a mixture A61K9/2077
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/26 Psychostimulants, e.g. nicotine, cocaine

Abstract

Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.

Claims

1. A solid, oral pharmaceutical composition comprising a plurality of particles, each comprising:

a core comprising methylphenidate or a pharmaceutical salt thereof and at least one pharmaceutically acceptable excipient;

a sustained release layer enclosing the core; and

a delayed release layer enclosing the sustained release layer,

wherein when the composition is orally administered to a human subject, there is a lag period of at least 5 hours during which the plasma concentration of methylphenidate or a pharmaceutical salt thereof is less than 10% of the maximum concentration (Cmax) and wherein the time to Cmax (Tmax) is between 12 and 19 hours after administration.

2. The solid, oral pharmaceutical composition of claim 1, wherein the core comprises a substantially spherical bead.

3. The solid, oral pharmaceutical composition of claim 1, wherein the core comprises methylphenidate hydrochloride.

4. The solid, oral pharmaceutical composition of claim 1, wherein the core comprises one or more excipients selected from polyvinyl pyrollidone, hydroxypropylmethyl cellulose, lactose, sucrose, microcrystalline cellulose and combinations of any thereof.

5. The solid, oral pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable excipient is microcrystalline cellulose.

6. The solid, oral pharmaceutical composition of claim 1, wherein the core comprises a non-pareil bead coated with a layer comprising the methylphenidate or a pharmaceutical salt thereof and at least one pharmaceutically acceptable excipient.

7. The solid, oral pharmaceutical composition of claim 1, wherein the delayed release layer comprises a pH dependent polymer or copolymer that is insoluble in aqueous medium at pH lower than 5.5.

8. The solid, oral pharmaceutical composition of claim 1, wherein the delayed release layer comprises cellulose acetate phthalate, cellulose acetate trimaletate, hydroxylpropyl methylcellulose phthalate, polyvinyl acetate phthalate, acrylic polymers, polyvinyl acetaldiethylamino acetate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate trimellitate, shellac, methacrylic acid copolymer, Eudragit L30D, Eudragit L100, Eudragit FS30D, Eudragit S100 or combinations of any thereof.

9. The solid, oral pharmaceutical composition of claim 1, wherein the delayed release layer comprises a plasticizer.

10. The solid, oral pharmaceutical composition of claim 9, wherein the plasticizer is dibutyl sebacate (DBS), tributyl citrate, acetyl tributyl citrate, acetyl triethyl citrate, mineral oil, castor oil or a fixed oil.

11. The solid, oral pharmaceutical composition of claim 8, wherein the delayed release layer comprises methacrylic acid copolymer Type B.

12. The solid, oral pharmaceutical composition of claim 8, wherein the delayed release layer comprises methacrylic acid copolymer Type B, mono- and diglycerides, dibutyl sebacate and polysorbate 80.

13. The solid, oral pharmaceutical composition of claim 1, wherein the sustained release layer comprises a water-insoluble and water-permeable polymer.

14. The solid, oral pharmaceutical composition of claim 13, wherein the sustained release layer further comprises a water soluble polymer.

15. The solid, oral pharmaceutical composition of claim 1, wherein the sustained release layer comprises a cellulose ether derivative, an acrylic resin, a copolymer of acrylic acid and methacrylic acid esters with quaternary ammonium groups, a copolymer of acrylic acid and a methacrylic acid ester or a combination of any thereof.

16. The solid, oral pharmaceutical composition of claim 1, wherein the sustained release layer comprises ethyl cellulose, hydroxypropyl cellulose and magnesium stearate.

17. The solid, oral pharmaceutical composition of claim 1, further comprising an abuse deterrent agent.

18. The solid, oral pharmaceutical composition of claim 1, further comprising a nasal irritant.

19. The solid, oral pharmaceutical composition of claim 18, wherein the nasal irritant is a capsaicinoid or sodium lauryl sulfate.

20. The solid, oral pharmaceutical composition of claim 1, wherein the plurality of particles are contained in a unit dose water soluble capsule.

21. The solid, oral pharmaceutical composition of claim 20, wherein the unit dose is from 1 mg to 150 mg methylphenidate or a pharmaceutical salt thereof.

22. The solid, oral pharmaceutical composition of claim 1, wherein the particles release no more than 10% of the total methylphenidate or a pharmaceutical salt thereof in the first five hours when placed in a simulated gastric environment.

24. The solid, oral pharmaceutical composition of claim 1, wherein the particles release no more than 10% of the total methylphenidate or a pharmaceutical salt thereof within the first 5 hours when the composition is placed in 700 ml aqueous solution of 0.1N HCl pH 1.1, for up to 2 hours followed by 2-6 hours in sodium phosphate buffer at pH 6.0;

followed by 6-20 hours in sodium phosphate buffer, pH 7.2 at 37°

C.±

0.5°

C., measured by the USP Apparatus 1.

25. The solid, oral pharmaceutical composition of claim 1, wherein the plasma area under the curve at 6 hours (AUC_0-6) after administration is less than about 5% of total plasma area under the curve at 48 hours after administration (AUC_0-48).

26. A water soluble capsule containing a unit dose of methylphenidate or a pharmaceutical salt thereof, wherein when the composition is orally administered to a human subject, there is a lag period of at least 5 hours during which the plasma concentration of methylphenidate or a pharmaceutical salt thereof is less than 10% of the maximum concentration (Cmax) and wherein the time to Cmax (Tmax) is between 12 and 19 hours after administration.

27. The water soluble capsule of claim 26, wherein the unit dose is from 1 to 150 mg methylphenidate or a pharmaceutical salt thereof.

28. A solid, oral pharmaceutical composition comprising a plurality of particles, each particle comprising:

a substantially spherical core comprising a therapeutic amount of methylphenidate or a pharmaceutical salt thereof and at least one pharmaceutically acceptable excipient;

a sustained release layer enclosing the core and comprising ethylcellulose, hydroxypropylcellulose, dibutyl sebacate and from 25-50% magnesium stearate; and

a delayed release layer enclosing the sustained release layer and comprising methacrylic acid copolymer B, mono- and di-glycerides and polysorbate 80.

29. The solid, oral pharmaceutical composition of claim 28, wherein the sustained release layer is coated on the bead to achieve from 15% to 35% weight gain and the delayed release layer is coated on the sustained release layer coated bead to achieve an additional 15% to 35% weight gain.